Trial · NCT00176826
T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders
NCT00176826, Phase 2, Phase 3, Terminated, Masonic Cancer Center, University of Minnesota; results first posted 2014-04-28
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders. Trials, record NCT00176826. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00176826
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders
- NCT number
- NCT00176826
- Status
- Terminated
- Phases
- Phase 2, Phase 3
- Enrollment
- 22 participants, actual
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Conditions
- Hemophagocytic Lymphohistiocytosis, X-Linked Lymphoproliferative Disorders, Chediak-Higashi Syndrome, Griscelli Syndrome, Immunologic Diseases, Langerhans-Cell Histiocytosis, Hematologic Diseases
- Interventions
- Stem Cell Transplant, Myeloablative conditioning regimen
- First posted
- 2005-09-15
- Last updated
- 2018-01-23
- Results first posted
- 2014-04-28
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Time to Transplant Engraftment | Day 100 Post Transplant | |
| Secondary | Number of Patients With Treatment Related Mortality. | Day 100 Post Transplant | |
| Secondary | Number of Patients Surviving (Disease-free) | 1 year | |
| Secondary | Number of Patients With Grade II-IV Graft-Versus-Host Disease (GVHD) | Day 100 Post Transplant | |
| Secondary | Number of Patients With Graft Failure | Day 100 Post transplant | |
| Secondary | Number of Patients With III-IV Graft-Versus-Host Disease (GVHD) | Day 100 Post Transplant | |
| Secondary | Number of Patients Surviving (Disease-free) | 3 years |
Source ClinicalTrials.gov
Outcomes7
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Time to Transplant Engraftment | Day 100 Post Transplant | days | MEAN | |
| SECONDARY | Number of Patients With Treatment Related Mortality. | Day 100 Post Transplant | participants | NUMBER | |
| SECONDARY | Number of Patients Surviving (Disease-free) | 1 year | participants | NUMBER | |
| SECONDARY | Number of Patients With Grade II-IV Graft-Versus-Host Disease (GVHD) | Day 100 Post Transplant | participants | NUMBER | |
| SECONDARY | Number of Patients With Graft Failure | Day 100 Post transplant | participants | NUMBER | |
| SECONDARY | Number of Patients With III-IV Graft-Versus-Host Disease (GVHD) | Day 100 Post Transplant | participants | NUMBER | |
| SECONDARY | Number of Patients Surviving (Disease-free) | 3 years | participants | NUMBER |
Source ClinicalTrials.gov
Results by group7
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Time to Transplant Engraftment | Intent-To-Treat | 19.8 | Standard Deviation 5.2 | days | |
| Number of Patients With Treatment Related Mortality. | Intent-To-Treat | 6 | participants | ||
| Number of Patients Surviving (Disease-free) | Intent-To-Treat | 14 | participants | ||
| Number of Patients With Grade II-IV Graft-Versus-Host Disease (GVHD) | Intent-To-Treat | 4 | participants | ||
| Number of Patients With Graft Failure | Intent-To-Treat | 2 | participants | ||
| Number of Patients With III-IV Graft-Versus-Host Disease (GVHD) | Intent-To-Treat | 1 | participants | ||
| Number of Patients Surviving (Disease-free) | Intent-To-Treat | 10 | participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Intent-To-Treat | 22 | |
| Overall Study | COMPLETED | Intent-To-Treat | 22 | |
| Overall Study | NOT COMPLETED | Intent-To-Treat | 0 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Secondary Malignancy | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Intent-To-Treat | 1 | 22 | 1 |
| serious | Death | General disorders | Intent-To-Treat | 1 | 22 | 1 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Intent-To-Treat | ||
| Total, other adverse events | Intent-To-Treat | 0 | 22 |
| Total, serious adverse events | Intent-To-Treat | 2 | 22 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00176826
GET https://conductscience.org/api/trials/v1/NCT00176826/registered